Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Outstanding: 27,300,779 for September 10, 2024
Monthly 5th Report
https://webfiles.thecse.com/8._Algernon_-_CSE_Form_7_-_August_2024.pdf?T0RnoT2MZl1XzWpHbNPjzdACkTKflj8P
Actually one of few stocks I would own at this point… God help us all if the Marxists win .. they usually kill people before they take power..
By all rights
The previous shareholders lost everything with failures..
You are buying a different proposition and insiders are invested..
It’s a better shot with DMT ..
I like it
Needed cash but if able will buy back in
Offering is $0.0892 $AGNPF or $0.12 $AGN
Someone and Insiders Buying the Offering
But Insiders except Kinley has also sold most those others held on the last real run which does look bad and would expect them to also sell these bought when price is up - JMO
https://ceo.ca/agn
My thinking is
Don’t sell
CRY or LAUGH My Ass Off
To me it’s sad but someone is collecting shares for some reason - Volume just not there for selling for the same @ the Market Price
Algernon Pharmaceuticals Announces Increase to Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE)
https://webfiles.thecse.com/2024-08-13_Algernon_Pharmaceuticals_Announces_Increase_to_209.pdf?80FkHRyx35jcD3V97cSqfn8Fr.W2Qq5G
Outstanding: 25,340,779 for August 7, 2024
Monthly 5th Report
https://webfiles.thecse.com/7._Algernon_-_CSE_Form_7_-_July_2024.pdf?xHwunyx5dN5BN0JDisNSwQ2.pH76QXG0
Closing of Private Placement
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Closing-of-Private-Placement?id=448835
Issued and outstanding securities following issuance:
25.5M Outstanding if closing tomorrow doesn’t change
25,340,779 Outstanding if closing the same that was released today and it Close 08/01/2024
Add the Broker pay which probably some in Cash and again paid the same in shares
In the past it was 8% cash and 8% shares and should read the 1st notice of this Offering
https://webfiles.thecse.com/Algernon_CSE_Form_9_-_Juy_2024.pdf?xwI_B_aF3yzpRKAETnDXGgVEQpZBtyNc
Says “To be provided @ the Closing, if any”
Quarter just posted for 5/31/2024
https://www.otcmarkets.com/otcapi/company/financial-report/408374/content
And here’s the MD&A posted
https://www.otcmarkets.com/otcapi/company/financial-report/408376/content
Algernon Announces Increase to Private Placement
Received a email just now but not posted yet OTC but here’s a quote and my math comes to 3,400,000 shares with Warrants the same plus Brokers fee paid in shares
Could This Stock Be the Next Bellus Cough Treatment?
https://www.streetwisereports.com/article/2024/07/17/could-this-stock-be-the-next-bellus-cough-treatment.html?utm_source=AGN-CNX
With all of the reverse splits .. my initial 50,000 shares is now 2,000. Lol go figure todays volume.
Looks like everyone split … 1,000 shares traded on some pretty good news
Study Showing 93% Cough Suppression with Ifenprodil
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Reports-Results-of-Study-Showing-93-Cough-Suppression-with-Ifenprodil?id=446850
Algernon Pharmaceuticals Announces Private Placement
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Private-Placement?id=446532
Outstanding: 21,940,779 for July 10, 2024
Monthly 5th Report
https://webfiles.thecse.com/6._Algernon_-_CSE_Form_7_-_June_2024.pdf?75v3v4P.m.qiZNOTcs14RpT7cYj_RqOU
Thank you,
It’s a p1 ..
It’s over..
Let’s go P2..
Dr Heijden did the presentation about CHDR at the Psychedelic conference,,,
https://www.icpr-conference.com/speakers/katelijne-van-der-heijden
Seems the Defense Authorization bill has support for research using these drugs for PTSD and "wounds of war". TBA?
The Netherlands is also doing research along with Arizona, Texas and Oregon and more.
Come on Chris, present our research, tell us how it went and try to get us involved with this new funding...JMHFO...GLTA...
https://www.youtube.com/shorts/8b50ODFdMEY
Anyone have presentation?
Outstanding: 21,940,779 for June 6, 2024
Monthly 5th Report
https://webfiles.thecse.com/5._Algernon_-_CSE_Form_7_-_May_2024.pdf?P_P1hgWsY8Cb0IuHXny8OiFIIn_NDM5g
AGN presentation to CHDR later this week. Sure hope we can finally see some real interesting news...GLTA...
Doubled the $$$’s in 3 mo’s…gonna rocket!!!$$$
Insiders look to be Adding Shares
https://ceo.ca/agn
NOTICE OF PROPOSED RESTRICTED SHARE UNIT (“RSU”) GRANT OR AMENDMENT
https://webfiles.thecse.com/CSE-Form-11-Notice-of-Proposed-RSUs_-_May_2024.pdf?vrVtJyueWiaIaZ1W3q33kPWkymhn1Uba
Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Engages-ICP-Securities-Inc-for-Automated-Market-Making-Services?id=441221
Outstanding: 21,840,722 for May 3, 2024
Monthly 5th Report
https://webfiles.thecse.com/4._Algernon_-_CSE_Form_7_-_April_2024.pdf?qaY9FopqdvCRcwssqB4AcLx7jW9LSh5C
200,000 commons to Maxim Group LLC for finding and Closing the Deal with Seyltx, Inc.
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-NeuroScience-and-the-Centre-for-Human-Drug-Research-to-Present-DMT-Phase-1-Stroke-Clinical-Data-at-the-Interdis?id=437889
Q&A and Webinar
Here is the link to the recording from last week’s webinar:
Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-CEO-Christopher-J-Moreau-to-Be-Featured-on-Radius-Researchs-Pitch-Deep-Dive-and-QA-Webinar-on-A?id=436475
Outstanding: 21,640,762 for April 4, 2024
Monthly 5th Report
https://webfiles.thecse.com/Algernon_-_CSE_Form_7_-_March_2024.pdf?Is_B3LCsJTGbo_e6ku57Z2tafpM1IKDQ
Is algernon neuro a traded stock by itself.
So no treatment for schemic stroke..
They do minimal things and then wait to see how bad the CNS was damaged..
Than try to rebuild what is lost..
When our drug roves itself..
It will need to be purchased everywhere
Stroke victims have access to treatment.. as the sooner you treat the better..
Our drug will not wait for patients .. caregivers will have to stick it..
Every ambulance, every hospital.. perhaps even every urgent care with me..
Depending on test for type of stroke and Pharma delivery system.. this could be like
Overdose or allergy med.. where they encourage everyone to have..
Depends on stroke test and safety of drug..
Micro dose DMT should be very safe..
That is worldwide in an aging population with increasing cardio system weakness..
$2million in bank.. if they can find clinical partner to share development cost with..
We are very blessed to be here
Neuroplasticity, dendritic spines, 1hr 40mins. He sites many papers, mostly in mouse/rat trials, in this presentation where neuroplasticity is observed, but it seems that the AGN 'microdosing for Stroke' concept is unique.
Yes, the when and where type of data for the clinical trials could be announced soon. Maybe Oregon where it's legal for research?
I've held this long already and will hold through the finish...
...GLTA...
The valuations are going to skyrocket on a positive phase 2a
I had found this presentation a long time ago. Finally found it again and it is a great video including neuroplasticity.
Sure great to see this all finally progressing.
“Investigating neuroplasticity in a clinical setting, as a potential new treatment approach for ischemic stroke patients, is a new and promising area of research,” said Christopher J. Moreau CEO of Algernon. “Algernon is a global leader in this important area of research, and we look forward to further advancing the stroke program through our planned Phase 2a DMT Stroke study.”
Phase 2a Stroke Study Design
Subjects with a confirmed diagnosis of ischemic stroke will be randomized in blinded fashion to receive either DMT or placebo. The primary outcome measure of the study will be safety, and information will be gained on measures of efficacy including preservation of brain tissue, motor recovery, depression and numerous biomarkers linked to the pathophysiology of stroke.
The veteran community has discussed TBI and PTSD issues and treatments involving Psycs. This group may also be a area of recruitment for future stroke/TBI research. There are already a few PTSD studies...
...GLTA...
Algernon going to move forward with 40 patient phase 2 for isechemic stroke.
Is there a Stroke Victim advocacy group which could help cover costs?
Can’t wait for results! 6 days of treatment..
40 patients.. normally a clinical trial takes forever..
How common is an ischemic stroke?
Strokes are very common. Worldwide, strokes rank second among the top causes of death. In the United States, they rank fifth. Strokes are also one of the leading causes of disability worldwide. Ischemic strokes make up about 85% of all strokes.
No shortage of need..
Stroke statistics
In 2021, 1 in 6 deaths from cardiovascular disease was due to stroke.1
Every 40 seconds, someone in the United States has a stroke.2 Every 3 minutes and 14 seconds, someone dies of stroke.1
Every year, more than 795,000 people in the United States have a stroke. About 610,000 of these are first or new strokes.2
About 185,000 strokes—nearly 1 in 4—are in people who have had a previous stroke.2
About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked.2
Stroke-related costs in the United States came to nearly $56.5 billion between 2018 and 2019.2 This total includes the cost of health care services, medicines to treat stroke, and missed days of work.
Stroke is a leading cause of serious long-term disability.2 Stroke reduces mobility in more than half of stroke survivors age 65 and older.2
I think the goal will be to administer the first sub psych dose of DMT immediately after diagnosis..
A positive phase 2a.. would be a very large step for algernon
“Investigating neuroplasticity in a clinical setting, as a potential new treatment approach for ischemic stroke patients, is a new and promising area of research,
Most medicines may be cross scripted..
When DMT becomes available for stroke..
I imagine there will be many interested in other illnesses of the CNS for DMT help
Patience and faith in character rewarded!
Great job Chris and algernon
Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Closing-of-the-Acquisition-of-its-Chronic-Cough-Research-Program-by-US-Based-Seyltx-f?id=435013
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |